-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
RVL Pharmaceuticals Plc - Ordinary Shares's Return On Capital Employed Overview
RVL Pharmaceuticals Plc - Ordinary Shares's Return On Capital Employed Overview
RVL Pharmaceuticals plc - Ordinary Shares (NASDAQ:RVLP) brought in sales totaling $10.02 million during Q3 according to data provided by Benzinga Pro. However, earnings decreased 19.33%, resulting in a loss of $14.45 million. RVL Pharmaceuticals plc - Ordinary Shares collected $8.45 million in revenue during Q2, but reported earnings showed a $12.11 million loss.
What Is Return On Capital Employed?
Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q3, RVL Pharmaceuticals plc - Ordinary Shares posted an ROCE of -0.21%.
It is important to keep in mind that ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but does not account for factors that could affect earnings and sales in the near future.
ROCE is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROCE shows RVL Pharmaceuticals plc - Ordinary Shares is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth.
For RVL Pharmaceuticals plc - Ordinary Shares, a negative ROCE ratio of -0.21% suggests that management may not be effectively allocating their capital. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns; poor capital allocation can be a leech on the performance of a company over time.
Analyst Predictions
RVL Pharmaceuticals plc - Ordinary Shares reported Q3 earnings per share at $-0.16/share, which did not meet analyst predictions of $-0.16/share.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
RVL Pharmaceuticals plc - Ordinary Shares (NASDAQ:RVLP) brought in sales totaling $10.02 million during Q3 according to data provided by Benzinga Pro. However, earnings decreased 19.33%, resulting in a loss of $14.45 million. RVL Pharmaceuticals plc - Ordinary Shares collected $8.45 million in revenue during Q2, but reported earnings showed a $12.11 million loss.
RVL製藥公司-普通股根據Benzinga Pro提供的數據,納斯達克(Sequoia Capital:RVLP)第三季度的銷售額總計1,002萬美元。然而,收益下降了19.33%,導致虧損1445萬美元。RVL PharmPharmticals plc-普通股在第二季度實現收入845萬美元,但公佈的收益顯示虧損1211萬美元。
What Is Return On Capital Employed?
什麼是已動用資本回報率?
Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q3, RVL Pharmaceuticals plc - Ordinary Shares posted an ROCE of -0.21%.
沒有背景的收益數據不清楚,可能很難作為交易決定的依據。已動用資本回報率(ROCE)通過衡量年度稅前利潤與企業已動用資本的比例,幫助從噪音中濾除信號。一般來說,較高的淨資產收益率意味著公司的成功增長,也是未來每股收益較高的跡象。第三季度,RVL PharmPharmticals plc-普通股的淨資產收益率為-0.21%。
It is important to keep in mind that ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but does not account for factors that could affect earnings and sales in the near future.
重要的是要記住,ROCE評估的是過去的績效,而不是用作預測工具。這是衡量一家公司近期表現的一個很好的指標,但沒有考慮到可能在不久的將來影響收益和銷售的因素。
ROCE is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROCE shows RVL Pharmaceuticals plc - Ordinary Shares is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth.
淨資產收益率是比較類似公司資本配置有效性的有力指標。相對較高的ROCE表明,RVL PharmPharmticals plc-普通股的運營效率可能高於行業內的其他公司。如果公司以目前的資本水準產生高利潤,其中一些資金可以再投資於更多的資本,這通常會帶來更高的回報,並最終實現每股收益(EPS)的增長。
For RVL Pharmaceuticals plc - Ordinary Shares, a negative ROCE ratio of -0.21% suggests that management may not be effectively allocating their capital. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns; poor capital allocation can be a leech on the performance of a company over time.
對於RVL PharmPharmticals plc-普通股,負ROCE比率為-0.21%,表明管理層可能沒有有效地配置他們的資本。有效的資本配置是一個積極的指標,表明一家公司將獲得更持久的成功和有利的長期回報;隨著時間的推移,糟糕的資本配置可能會拖累公司的業績。
Analyst Predictions
分析師預測
RVL Pharmaceuticals plc - Ordinary Shares reported Q3 earnings per share at $-0.16/share, which did not meet analyst predictions of $-0.16/share.
RVL PharmPharmticals plc-普通股公佈第三季度每股收益為-0.16美元,低於分析師預測的-0.16美元。
This article was generated by Benzinga's automated content engine and reviewed by an editor.
本文由Benzinga的自動內容引擎生成,並由編輯審閱。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧